Article Text

Download PDFPDF
FIGO stage IIIC endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival
  1. R. E. Bristow*,
  2. M. L. Zahurak,
  3. C. J. Alexander*,
  4. R. C. Zellars and
  5. F. J. Montz*
  1. * The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, Maryland
  2. Department of Biostatistics, Johns Hopkins Oncology Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland
  3. Department of Radiation Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland
  1. Address correspondence and reprint request to: Robert E. Bristow, MD, The Kelly Gynecologic Oncology Service, Department of Gynecology & Obstetrics, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps #289, Baltimore, MD 21287–1248. Email: rbristo{at}jhmi.edu

Abstract

The objective of this study was to evaluate the potential survival benefit of debulking macroscopic adenopathy and other clinical prognostic factors among patients with node-positive endometrial carcinoma. Demographic, operative, pathologic, & follow-up data were abstracted retrospectively for 41 eligible patients with FIGO stage IIIC endometrial cancer. Survival curves were generated using the Kaplan-Meier method and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. All patients had positive pelvic lymph nodes and 20 patients (48.8%) had positive para-aortic lymph nodes. Postoperatively, all patients received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 patients received chemotherapy. The median disease-specific survival (DSS) time for all patients was 30.6 months (median follow-up 34. 0 months). Patients with completely resected macroscopic lymphadenopathy had a significantly longer median DSS time (37.5 months), compared to patients left with gross residual nodal disease (8.8 months, P = 0.006). On multivariate analysis, independent predictors of DSS were gross residual nodal disease (HR 7.96, 95% CI 2.54–24.97, P < 0. 001), age ≥ 65 years (HR 6.22, 95% CI 2.05–18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07–0.76, P = 0.016). We conclude that in patients with stage IIIC endometrial carcinoma, complete resection of macroscopic nodal disease and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.

  • chemotherapy
  • lymphadenopathy
  • radiation therapy
  • surgery

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.